QRG Capital Management Inc. Buys 10,421 Shares of Stryker Corporation $SYK

QRG Capital Management Inc. grew its position in Stryker Corporation (NYSE:SYK) by 17.2% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 70,969 shares of the medical technology company’s stock after purchasing an additional 10,421 shares during the quarter. QRG Capital Management Inc.’s holdings in Stryker were worth $23,320,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in SYK. Vanguard Group Inc. grew its holdings in Stryker by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after acquiring an additional 133,892 shares in the last quarter. State Street Corp lifted its position in shares of Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares during the period. Geode Capital Management LLC boosted its stake in shares of Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Wellington Management Group LLP increased its holdings in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares during the period. Finally, Alliancebernstein L.P. raised its stake in Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SYK. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. Truist Financial restated a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a report on Monday, May 4th. JPMorgan Chase & Co. cut their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Citigroup reduced their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Finally, Robert W. Baird set a $385.00 target price on shares of Stryker in a research report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average target price of $395.33.

Stryker Stock Performance

Shares of NYSE SYK opened at $326.41 on Friday. The company has a 50 day simple moving average of $309.80 and a two-hundred day simple moving average of $338.87. The stock has a market cap of $125.13 billion, a price-to-earnings ratio of 37.78, a PEG ratio of 2.09 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.